Medicinal Chemistry & Drug Development

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

The authors review unique methodological challenges in psychedelic clinical trials—particularly pronounced subjective drug effects, strong media-driven expectancies and frequent unmasking—that heighten susceptibility to placebo and nocebo bias. They provide practical recommendations on study design, recruitment and selection, disclosure strategies, choice of active placebo and measurement of expectations and masking efficacy to reduce bias and better isolate treatment‑specific effects.

Authors

  • Joshua Woolley
  • Jordan Aday
  • Boris Heifets

Published

Psychopharmacology
meta Study

Abstract

Rationale

Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research.

Objective

In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research.

Results

We found that although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants’ expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies concern study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy.

Conclusion

Incorporating these design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increase the ability to discern treatment-specific effects of psychedelic therapy

Available with Blossom Pro

Research Summary of 'Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials'

Introduction

Aday and colleagues situate their paper in the context of a rapid expansion of clinical research on psychedelic medicines alongside longstanding concerns about expectancy effects, control conditions and effective masking. Earlier research from both psychotherapy and pharmacology trials has long recognised that non-specific factors—such as spontaneous remission, regression to the mean, Hawthorne effects, placebo and nocebo responses—can produce apparent clinical change independent of a tested intervention. Psychedelic trials face these general challenges plus additional, field-specific problems: highly salient acute subjective effects that make masking difficult, widespread positive media and cultural “hype” that elevate participants' outcome expectations, and interactions between unmasking and expectations that may amplify placebo or nocebo influences. This paper aims to review the methodological challenges specific to psychedelic clinical trials and to offer practical recommendations to improve their rigour. Rather than testing a new treatment, the authors undertake a scoping synthesis of prior literature and trial practices to identify common sources of bias, evaluate previous masking strategies and propose an integrated framework of design, recruitment, procedural and analytic measures to reduce expectancy-related confounds. The objective is to improve the ability of future trials to distinguish treatment-specific effects of psychedelic therapy from treatment-nonspecific influences.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Study Details

References (41)

Papers cited by this study that are also in Blossom

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects

Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Is Ecstasy an “Empathogen”? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others

Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)

213 cited
Effects of MDMA on attention to positive social cues and pleasantness of affective touch

Bershad, A. K., Mayo, L. M., Van Hedger, K. et al. · Neuropsychopharmacology (2019)

Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users

Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)

102 cited
LSD enhances suggestibility in healthy volunteers

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)

257 cited
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?

Carhart-Harris, R. L., Wagner, A. C., Agrawal, M. et al. · Journal of Psychopharmacology (2021)

40 cited
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique

Doblin, R. · Journal of Transpersonal Psychology (1991)

Show all 41 references
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)

32 cited
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy

Gukasyan, N., Nayak, S. · Preprints (2020)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity

Hartogsohn, I. · Frontiers in Human Neuroscience (2018)

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology

Hartogsohn, I. · Journal of Psychopharmacology (2016)

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

112 cited
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

Kuypers, K. P. C., Erritzoe, D., Knudsen, G. M. et al. · Journal of Psychopharmacology (2019)

Reactions to psilocybin administered in a supportive environment

Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis

Leger, R. F., Unterwald, E. M. · Journal of Psychopharmacology (2021)

Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin

MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)

350 cited
Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences

Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)

278 cited
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.

Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)

99 cited
Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials

Muthukumaraswamy, S., Forsyth, B., Lumley, T. · Expert Review of Clinical Pharmacology (2021)

A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)- assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)

328 cited
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects

Olson, D. E. · ACS Pharmacology and Translational Science (2020)

Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency

Pace, B. A., Devenot, N. · Frontiers in Psychology (2021)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry

Sessa, B. · Journal of Psychoactive Drugs (2014)

Registered clinical studies investigating psychedelic drugs for psychiatric disorders

Siegel, A. N., Lipsitz, O., Gill, H. et al. · Journal of Psychiatric Research (2021)

Psychedelics alter metaphysical beliefs

Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)

A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats

Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study

Van Elk, M., Fejer, G., Lempe, P. et al. · Psychopharmacology (2021)

42 cited
Examining changes in personality following shamanic ceremonial use of ayahuasca

Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)

53 cited
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

Williams, N. R., Heifets, B. D., Bentzley, B. S. et al. · Molecular Psychiatry (2019)

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

Yoon, G., Petrakis, I. L., Krystal, J. H. · JAMA Psychiatry (2019)

132 cited

Cited By (49)

Papers in Blossom that reference this study

Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use

Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

Stocker, K., Hartmann, M., Barrett, F. S. et al. · Religion, Brain & Behavior (2026)

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

Magnitude of Response in Treatment and Control Groups within Psychedelic Trials for Psychiatric Disorders: A Meta-Analysis

Meshkat, S., Lin, Q., Sousa-Ho, R. et al. · European Psychiatry (2026)

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial

Schindler, E. A. D., Gottschalk, C. H., Pittman, B. P. et al. · Headache (2025)

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)

An international Delphi consensus for reporting of setting in psychedelic clinical trials

Pronovost-Morgan, C., Greenway, K. T., Roseman, L. · Nature Medicine (2025)

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)

10 cited
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, proof-of-concept clinical trial

Aday, J. S., Mcafee, J., Conroy, D. A. et al. · Frontiers in Pain Research (2025)

Show all 49 papers
Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study

Rucker, J., Butler, M., Hambleton, S. et al. · Headache (2024)

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Nicholas, C. R., Banks, M. I., Lennertz, R. L. et al. · Translational Psychiatry (2024)

Clinically relevant acute subjective effects of psychedelics beyond mystical experience

Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)

Do classic psychedelics increase the risk of seizures? A scoping review

Soto-Angona, Ó., Fortea, A., Fortea, L. et al. · European Neuropsychopharmacology (2024)

Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives

Aday, J. S., Boehnke, K. F., Herberholz, M. et al. · Journal of Psychedelic Studies (2024)

Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)

Expectancy effects in psychedelic trials

Szigeti, B., Heifets, B. D. · Biological Psychiatry (2024)

49 cited
Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis

Matsingos, A., Wilhelm, M., Noor, L. et al. · Frontiers in Psychiatry (2024)

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)

Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study

Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · Scientific Reports (2024)

Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study

Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Psychoactive Drugs (2024)

15 cited
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study

Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)

Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)

10 cited
Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers

Mathai, D. S., Hilbert, S., Sepeda, N. D. et al. · Psychedelic Medicine (2023)

6 cited
Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients

Lii, T. R., Smith, A. E., Flohr, J. R. et al. · Nature Mental Health (2023)

68 cited
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

History repeating: guidelines to address common problems in psychedelic science

Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)

94 cited
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)

375 cited
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis

Hietamies, T. M., Mcinnes, L. A., Klise, A. J. et al. · Journal of Affective Disorders (2023)

Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials

Noorani, T. N., Bedi, G., Muthukumaraswamy, S. · Psychological Medicine (2023)

21 cited
Harnessing placebo: Lessons from psychedelic science

Pronovost-Morgan, C., Hartogsohn, I., Ramaekers, J. G. · Journal of Psychopharmacology (2023)

Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis

Muthukumaraswamy, S. · Psyarxiv (2023)

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)

39 cited
Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study

Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression

Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)

Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults

Weiss, B., Sleep, C., Miller, J. D. et al. · Journal of Personality Disorders (2023)

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Sloshower, J. A., Skosnik, P. D., Safi-Aghdam, H. et al. · Journal of Psychopharmacology (2023)

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice

Aday, J. S., Skiles, Z., Eaton, N. et al. · Psychedelic Medicine (2023)

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)

Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use

Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)

Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury

Gray, J. C., Murphy, M., Carter, S. E. et al. · Military Medicine (2022)

8 cited
Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Headache (2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)

Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in
Great Expectations: Recommendations for improving... — Research Summary & Context | Blossom